Media stories about FRESENIUS SE &/S (OTCMKTS:FSNUY) have trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than 6,000 news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. FRESENIUS SE &/S earned a daily sentiment score of -2.67 on their scale. InfoTrie also assigned headlines about the company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted FRESENIUS SE &/S’s ranking:
- Delaware Supreme Court Upholds Ruling Allowing Fresenius to End Akorn Deal (advfn.com)
- Fresenius Wins Ruling on Canceled Buyout; Akorn Shares Fall (finance.yahoo.com)
- Fresenius, Fresenius Medical Care Shares Fall on Revised Outlook (advfn.com)
- European markets rally after global sell-off; Fresenius SE shares tank 10% (cnbc.com)
- Fresenius Expects Mid-Single Digit Organic Growth In The Medium-Term, After Strong Investment Year 2019 (advfn.com)
Shares of FSNUY stock opened at $11.06 on Friday. The firm has a market cap of $30.20 billion, a P/E ratio of 12.02, a PEG ratio of 1.45 and a beta of 1.18. FRESENIUS SE &/S has a twelve month low of $11.00 and a twelve month high of $22.05. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.92 and a current ratio of 1.18.
FRESENIUS SE &/S (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, October 31st. The company reported $0.23 earnings per share for the quarter. The business had revenue of $9.52 billion for the quarter. FRESENIUS SE &/S had a return on equity of 12.53% and a net margin of 5.91%. Equities research analysts expect that FRESENIUS SE &/S will post 1.04 EPS for the current fiscal year.
Separately, Zacks Investment Research upgraded FRESENIUS SE &/S from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research report on Tuesday, November 6th.
TRADEMARK VIOLATION NOTICE: “Negative Media Coverage Extremely Likely to Affect FRESENIUS SE &/S (FSNUY) Share Price” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/12/08/negative-media-coverage-extremely-likely-to-affect-fresenius-se-s-fsnuy-share-price.html.
FRESENIUS SE &/S Company Profile
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
See Also: Systematic Risk and Investors
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.